666 related articles for article (PubMed ID: 24343302)
1. Tumour-associated mutant p53 drives the Warburg effect.
Zhang C; Liu J; Liang Y; Wu R; Zhao Y; Hong X; Lin M; Yu H; Liu L; Levine AJ; Hu W; Feng Z
Nat Commun; 2013; 4():2935. PubMed ID: 24343302
[TBL] [Abstract][Full Text] [Related]
2. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.
Zheng T; Wang J; Zhao Y; Zhang C; Lin M; Wang X; Yu H; Liu L; Feng Z; Hu W
Nat Commun; 2013; 4():2996. PubMed ID: 24356649
[TBL] [Abstract][Full Text] [Related]
3. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
[TBL] [Abstract][Full Text] [Related]
4. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
5. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
6. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
[TBL] [Abstract][Full Text] [Related]
7. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
Elife; 2015 Aug; 4():. PubMed ID: 26271008
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
9. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
10. Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome.
Zhang Y; Hu Y; Fang JY; Xu J
Oncotarget; 2016 Mar; 7(10):11056-66. PubMed ID: 26840456
[TBL] [Abstract][Full Text] [Related]
11. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
Kong LR; Ong RW; Tan TZ; Mohamed Salleh NAB; Thangavelu M; Chan JV; Koh LYJ; Periyasamy G; Lau JA; Le TBU; Wang L; Lee M; Kannan S; Verma CS; Lim CM; Chng WJ; Lane DP; Venkitaraman A; Hung HT; Cheok CF; Goh BC
Nat Commun; 2020 Apr; 11(1):2086. PubMed ID: 32350249
[TBL] [Abstract][Full Text] [Related]
12. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
[TBL] [Abstract][Full Text] [Related]
14. β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer.
Tocci P; Cianfrocca R; Di Castro V; Rosanò L; Sacconi A; Donzelli S; Bonfiglio S; Bucci G; Vizza E; Ferrandina G; Scambia G; Tonon G; Blandino G; Bagnato A
Nat Commun; 2019 Jul; 10(1):3196. PubMed ID: 31324767
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.
Alvarado-Ortiz E; de la Cruz-López KG; Becerril-Rico J; Sarabia-Sánchez MA; Ortiz-Sánchez E; García-Carrancá A
Front Cell Dev Biol; 2020; 8():607670. PubMed ID: 33644030
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
Schulz-Heddergott R; Moll UM
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
18. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
19. Yin Yang 1 promotes the Warburg effect and tumorigenesis via glucose transporter GLUT3.
Wang Y; Wu S; Huang C; Li Y; Zhao H; Kasim V
Cancer Sci; 2018 Aug; 109(8):2423-2434. PubMed ID: 29869834
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
